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Abstract  
The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) was developed to assess 
cognitive and behavioural changes in an anterior frontotemporal syndrome (executive 
functions, language, fluency and behaviour), common in Amyotrophic Lateral Sclerosis 
(ALS) and also assesses posterior cerebral dysfunction (memory and visuospatial abilities).  
Objectives: To validate the ECAS in behavioural variant Frontotemporal Dementia 
(bvFTD) without ALS, as compared with Alzheimer’s Disease (AD), against 
comprehensive neuropsychological assessment. Compare its sensitivity to that of the 
Addenbrooke’s Cognitive Examination (ACE-III) and investigate behavioural changes in 


















Methods: Retrospective study of 16 people with bvFTD (without ALS), 32 with AD, and 
48 healthy controls completed the ECAS, ACE-III and extensive neuropsychological 
assessment. 
Results: The ECAS showed higher sensitivity (94%) and marginally lower specificity 
(96%) than the ACE-III for both the bvFTD and AD groups. The anterior composite subscore 
was sensitive for bvFTD (94%), and slightly less so for AD (84%), while the posterior 
composite subscore was sensitive for AD (97%), and less so for bvFTD (75%). All people with 
bvFTD that were impaired on the ECAS total and anterior composite scores were also impaired 
on the anterior function’s tests of the neuropsychological assessment. A cut-off of 4 or more 
behavioural domains affected differentiated well between the bvFTD and AD groups, while a 
qualitative analysis of the behavioural interview found different themes between groups. 
Conclusions: The ECAS is a valid and sensitive assessment for bvFTD without ALS and 
for AD. The carer behavioural interview makes it particularly suitable to detect behavioural 
abnormalities related to frontal lobe disorders. 
 
Key words: ECAS, ACE-III, frontotemporal dementia, Alzheimer’s disease, screen, cognition, 
behaviour, dementia, neuropsychology, qualitative 
 
Key points:  
1. The ECAS showed higher sensitivity (94%) and specificity (96%) for both the 
bvFTD and AD groups than the ACE-III. 
2. The ECAS performed well against standard comprehensive neuropsychological 
assessment with perfect concordance between ECAS Total and Anterior functions 
composite scores, and performance on the anterior functions’ tests of the 


















functions composite scores also showed good validity against the posterior 
functions’ tests of the neuropsychology assessment for the AD group. 
3. The most recurrent abnormal behaviour for the bvFTD group was loss of 
sympathy/empathy (100%), while the most recurrent theme for AD was loss of interest 
in normal activities (56%). Important thematic differences between diagnoses were 
(26%) lack of awareness and (66%) lack of manners in people with bvFTD, while AD 
patients (33%) had a loss of self-confidence. 
 
Introduction 
Amyotrophic Lateral Sclerosis (ALS) is the most common form of Motor Neurone Disease 
and has been typically characterised as a rapid neurodegenerative disease affecting 
movement (1). However, between 10-15% of people with ALS fulfil a diagnosis of 
frontotemporal dementia, most commonly the behavioural variant (bvFTD), and an 
additional 35% have milder and more specific cognitive impairment indicating a full 
spectrum of frontotemporal dysfunction (2,3). The Edinburgh Cognitive and Behavioural 
ALS Screen (ECAS) was developed to assess these cognitive and behaviour changes (4). It 
is designed to accommodate physical disability common in ALS, allowing for both written 
and spoken responses. As such, it is also well suited to assess cognitive functions in other 
diseases affecting motor functions, including Parkinson’s Disease and Progressive 
Supranuclear Palsy (5). 
 
The ECAS comprises a brief assessment of cognitive domains typically affected by anterior 
cerebral dysfunction: executive functions (including social cognition), language and verbal 
fluency, characteristically impaired in ALS. It also includes assessment of the domains 


















visuospatial abilities. These were included to differentiate between the frontotemporal 
syndrome in ALS, and cognitive deficits resulting from other disorders common in older 
adults, namely Alzheimer’s Disease (AD) (6). Furthermore, the ECAS includes a 
behavioural interview with carers which assesses five domains based on the diagnostic 
criteria for bvFTD (7).  
 
This brief assessment is sensitive in detecting mild cognitive impairment (without dementia) 
in ALS with impairments in executive, language and fluency (4). It has also been validated 
against comprehensive neuropsychological testing in ALS, showing good sensitivity and 
specificity (8,9) and convergent validity against other screening tests; the Montreal Cognitive 
Assessment (MoCA), Frontal Assessment Battery (FAB), Consortium to Establish a Registry 
for Alzheimer’s Disease plus Scale (CERAD plus) and Addenbrooke’s Cognitive Examination 
(ACE-III) (10-12). A recent study demonstrated that both bvFTD with and without ALS were 
impaired on the ECAS against a healthy control group (13). The study showed evidence of 
convergent validity with four standard neuropsychological tests of naming, spelling, cognitive 
inhibition (executive function) and social cognition. However, the study did not investigate the 
clinical utility of the test by validating performance against comprehensive clinical 
neuropsychology assessment or against more routinely used brief cognitive 
assessment/screening measures. The ACE-III is a commonly used cognitive screen, developed 
to assess different types of dementia; and was originally validated in both AD and FTD (14). 
However, its sensitivity in the detection of bvFTD has been inconsistent (15-18). Although the 
ACE-III includes an assessment of fluency (letters and animals), it lacks other tests of executive 
functions, impairment of which form part of the diagnostic criteria of bvFTD.  
 


















pattern with frontal lobe dysfunction beginning in the orbitofrontal cortex in bvFTD (19); 
and medial temporal and occipitoparietal regions in AD (20,21). Recent studies have 
revealed that the ECAS composite score, compromising memory and visuospatial 
performance, was as sensitive to AD as the ACE-III (22) and was effective at differentiating 
ALS from AD in a Greek population (6). 
 
This study aimed to validate the ECAS and further determine its clinical utility in detecting 
the cognitive and behavioural impairments in bvFTD in comparison with AD. Specifically 
the aims were to: 
1. Determine whether the cognitive section of the ECAS is successful in detecting bvFTD 
without ALS, as compared with AD and healthy controls, and in comparison, with the 
ACE-III. We hypothesize that the people with bvFTD would perform more poorly on 
the ECAS domains typically affected by anterior cerebral dysfunction (executive 
functions, fluency, language). In contrast people with AD would perform more poorly 
on those affected by more posterior cerebral dysfunction (memory and visuospatial). 
2. Determine the validity of the ECAS total score, and composite scores against a 
comprehensive clinical neuropsychological assessment.  
3. Investigate the utility of the behavioural interview and determine whether the themes 





In this retrospective study we analysed data collected as part of routine clinical 


















(±9.38, 38-72) and education of 12.56 years (±3.24, 10-20)), and 32 with AD (16 males, 
mean age of 61.18 years (±5.87, 49-71) and education of 12.13 years (±2.17, 10-18)) from 
the Edinburgh Cognitive Diagnosis Audit Research and Treatment Register (DART), 
hosted by the Anne Rowling Regenerative Neurology Clinic and the University of Edinburgh. 
For the quantitative analysis of the behavioural data, we analysed data from a subgroup of 15 
people with bvFTD and 24 with AD.  Qualitative data was retrospectively obtained from 
available hand written verbatim records of interviews with the carers/relatives of 15 people 
with bvFTD (10 males, mean age of 64.13 years (±8.80, 39-76) and education of 12.60 
years (±2.99, 10-18)), and 25 people with AD (11 males, mean age of 62.80 years (±5.23, 
53-71) and education of 12.04 years (±2.24, 10-18)), (13 and 23 of which were included in 
the quantitative analyses of the behavioural interview).  
 
Diagnoses were supported by magnetic resonance imaging (MRI) brain and HMPAO-SPECT 
imaging findings; measures of cerebrospinal (CSF) total Tau, Phosphorylated Tau, and beta 
amyloid (Ab1-42); and/or disease-causing mutations identified following a neurodegenerative 
gene panel analysis. Diagnoses were made according to consensus criteria: Rascovsky et al. 
(7) for bvFTD and McKhann et al. (23) for AD.     
Retrospective data of healthy participants (n=48, 29 males) was from a larger sample 
previously described by De Icaza Valenzuela et al. (12). Participants were selected to match 
the patient groups in age (60.06 years (±11.92, 38-78)) and education (13.66 years (±3.03, 
9-19)). They were previously recruited from the local population and the Psychology Volunteer 
Panel of the University of Edinburgh. All were native English speakers without neurological 




















Neuropsychological testing included the ECAS, both cognitive and behavioural sections (4) 
and the ACE-III (14). Impairments were determined using published abnormality cut-offs. The 
ECAS evaluates the domains of: memory, visuospatial, fluency, language and executive 
functions. In addition to the total score, the test also provides a composite score for more 
anterior cerebral functions (fluency, executive, and language, originally termed ALS-specific 
as these were the functions typically affected in ALS) and one for more posterior cerebral 
functions (memory and visuospatial, originally termed ALS non-specific). The ECAS also 
includes a short behavioural interview that is completed with a relative/carer of the patient. 
This interview includes 10 questions examining: disinhibition, apathy, loss of sympathy or 
empathy, perseveration, hyperorality or change in food preferences, and psychotic symptoms 
(4, see http://ecas.psy.ed.ac.uk). The carer is asked whether each behaviour occurs, to describe, 
and give examples of the behaviour. 
  
Further extensive comprehensive neuropsychological assessment included a range of tests 
which are routinely clinically undertaken (Supplementary 1). Impairment for each test was 
determined according to their published cut-off scores for abnormality or based on the 5th 
percentile of published normative data. To determine the validity of the ECAS anterior and 
posterior functions composite scores against more extensive testing, the neuropsychological 
tests were grouped according to the cognitive domains which correspond with the ECAS 
(executive, language, fluency, memory, and visuospatial). Each domain was assessed by two 
or three neuropsychological tests, and an impairment in a domain was determined when 
performance on at least one of the tests was impaired. A deficit in anterior functions was 
classified when one of the following domains was impaired: fluency, language, and/or 
executive functions. A deficit in posterior functions was classified when either visuospatial 



















Patient data was collected from the Edinburgh Cognitive Diagnosis Audit Research and 
Treatment (DART) Register, South East Scotland A Research Ethics Committee approval 
12/SS/0196, IRAS no 103819. The testing of healthy control participants was approved by The 




The data were analysed using SPSS statistics version 22. One-way between groups analysis of 
variance (ANOVA) were undertaken on parametric data to assess the difference between 
groups. Homogeneity of variance for all variables was unequal as determined by Levene’s test, 
and we therefore used Welch’s ANOVA with Games-Howell post hoc tests. ROC curves 
assessed the sensitivity and specificity of the ECAS and the ACE-III to detect diagnosis of 
bvFTD and probable AD against healthy controls.   
Transcripts of the behavioural interviews were analysed thematically using the Framework 
Analysis Method (24), by two raters independently. The results of both analyses were 





Sensitivity of the ECAS in detecting bvFTD and AD as compared with the ACE-
III 
There was a significant difference between healthy controls and the two patient groups (bvFTD 


















but the two patient groups did not significantly differ in any of these scores (see Table 1). 
Fifteen of sixteen (94%) of the bvFTD group were impaired on the ECAS Total and the ECAS 
anterior functions composite score, while 12 (75%) were impaired on the posterior functions 
composite score. Fourteen of the bvFTD group also completed the ACE-III, of whom 11 (79%) 
scored within the abnormal range (82 or below) while a further patient scored within the 
borderline range (82-88). In the assessment of the AD group, 30/32 (94%) were impaired on 
the ECAS Total score, and 31 (97%) were impaired in the ECAS posterior functions composite 
score, while 27 (84%) were impaired on the anterior functions composite score. Twenty-five 
of the AD group completed the ACE-III, of which 23 (92%) scored below the cut-off of 88; 
and 20 (80%) scored below the cut-off of 82. The frequency of impairment on the ECAS was 
identical when using abnormality cut-offs adjusted for age and education (12). 
 
The ECAS total cognitive score showed high and equal sensitivity and specificity (94%, 96% 
respectively) at detecting both bvFTD and AD using the established cut-off score of 105. In 
comparison, the ACE-III was less sensitive but had an equal specificity at detecting either 
diagnosis (bvFTD 79%,98%, AD 83%,98%) (see Table 2). The ECAS total score was the most 
sensitive measure in detecting bvFTD, followed closely by the ECAS anterior functions 
composite score (see Figure 1a). The ECAS posterior functions composite score was the most 
sensitive measure in detecting AD, followed by the ECAS total score (see Figure 1b). 
Although, both composite scores were sensitive to both diagnoses, there was no significant 
difference in any of the ECAS cognitive scores between patient groups. The anterior composite 
score of the ECAS had a sensitivity of 52% and a specificity of 43% to differentiate between 
the bvFTD and AD groups with a cut-off of 62. The posterior composite score of the ECAS 


















groups with a cut-off of 23. The ECAS Total Score had a sensitivity of 76% and a specificity 
of 29% to differentiate between the AD and bvFTD groups with a cut-off of 91. 
 
Power analyses were calculated in G*Power (25) for the comparison of means on the ECAS 
posterior functions. The current comparison of the bvFTD group with the healthy control group 
had a large effect size (d= 2.52) and a power of .99 when using an alpha of 0.05; however, the 
comparison of the bvFTD group and the AD group had a medium effect size (d= 0.55) and a 
much reduced power of .55 when using an alpha of 0.05. Therefore, power may have been an 
issue in detecting a difference between bvFTD and AD patients on the ECAS composite scores. 
 
Validation of the ECAS against Comprehensive Neuropsychological Assessment 
Thirteen of the bvFTD group also completed the comprehensive neuropsychological 
assessment. Twelve (92%) were impaired on at least one of the anterior cerebral function 
domains of the full assessment (Fluency and/or Language and/or Executive), and all of these 
were also impaired on the ECAS Total and ECAS anterior functions composite scores giving 
perfect concordance, with 100% sensitivity and specificity. The ACE-III had a good sensitivity 
(82%, specificity 100%) to the anterior cerebral function domains of the neuropsychological 
assessment. One person with bvFTD was impaired only on the posterior functions of the full 
neuropsychological assessment, and was not impaired on either brief assessment, although fell 
in the borderline range on the ECAS Total score (scored 108). Of note this person had five 
behavioural domain changes. The profile of impairment across the tests are summarised in 
Supplementary Table 2. 
 
Two AD participants did not undertake the neuropsychological assessment, but all who did 


















Visuospatial). However, the ACE-III did not detect five patients, the ECAS total score could 
not detect two patients, and the ECAS posterior composite score could not detect one patient 
who were impaired on the posterior functions of the full neuropsychological assessment.  
Therefore, the sensitivity of these brief assessments at detecting posterior cognitive dysfunction 
as determined by full neuropsychological assessment, was 93% ECAS Total score, 97% ECAS 
posterior score, and 79% ACE-III all with a specificity of 100%. 
 
Behavioural Interview 
The carers/relatives of 15 people with bvFTD and 24 people with AD completed the 
behavioural interview. The majority of the bvFTD group had behavioural changes in five 
domains, whereas the majority of the AD group had behavioural changes in two domains (see 
Figure 2). The most common behavioural changes were disinhibition, apathy and loss of 
empathy in bvFTD and apathy and perseverative behaviour in AD (see Supplementary Table 
3). The total number of behavioural domains impaired differentiated between bvFTD and AD 
with a sensitivity of 79%, specificity 87% using a cut-off of 4 or more behavioural domains 
affected. 
 
Thematic Analysis of Carer Behavioural Interview 
Several themes distinguished the bvFTD from the AD patients (see Table 3). The themes below 
were present in bvFTD only.   
 Immediacy/ Impatience (66%) – “If he wants to do something in the moment he does, 
regardless of the circumstances. He just cannot stop himself”. 
 Manners (66%) – “Puts his feet up on the chair in restaurants. He eats off other people’s 
plates and licks the plates in public” 


















 Egocentrism (33%) – “Only displays interest if it is related to him or when he is the 
center of attention, if not he switches off completely” 
 Binge eating (46%) – “Eats non-stop…loses control” 
 Strange beliefs (20%) – “Won’t wash the front of her head because of her diagnosis of 
FTD” 
 Lack of awareness (26%) – Upset about restrictions in his driver’s license. Becomes 
verbally aggressive if he feels relative is suggesting that he has dementia 
 Not the same person (46%) – “Not my mum. Used to be incredibly polite and now quite 
rude” 
 Accidental oversights or Mistakes (60%) – “Exploded flask because he put it directly 
on the hob” 
 
The themes reported for AD only were: 
 Eating less or lost weight (32%) – “Doesn’t eat well or the full meal” 
 Avoids cooking (24%) – “…scared to touch something hot” 
 Stopped reading (24%) 
 Misplacing items (8%) – “Teapot in the fridge” 
 Difficulties solving problems (20%) – “Couldn’t figure out how to plough a field he 
did every year” 
 Lost confidence (33%) – “Apologizes a lot” 
The most common themes in the people with bvFTD were: loss of sympathy/empathy (100%)- 
“Always used to be caring and giving, but not so much anymore”, loss of interest in normal 
activities/hobbies (80%), reduced social interest, even with family and close friends (80%), 


















carbohydrates (80%), buying impulsively (73%)- “cannot pass a shop without buying things 
immediately”, and compulsive behaviour (73%)- “Besotted with puzzles, does them 
obsessively”. The most common themes in AD were: loss of interest in normal 
activities/hobbies (56%), impulsive decisions (33%), offensive/inappropriate jokes or 





The ECAS was successful in detecting the cognitive changes present in bvFTD and AD 
compared to healthy controls, although there were no significant group differences in scores 
between the two types of dementia. Using published abnormality cut-offs (4), the ECAS 
anterior functions composite score (sensitivity of 94% and a specificity of 92%) (which 
comprises the domains of Fluency, Executive Functions and Language) and the ECAS 
Total Score (sensitivity 94% and specificity 96%) were the most effective measures in our 
study at detecting bvFTD when compared to healthy controls. The percentage of 
impairment on the ECAS in the bvFTD group in our sample (94%) was similar to what has 
been previously reported (91%) (13). The posterior functions composite score (Memory 
and Visuospatial domains) (sensitivity 97% and specificity 96%) was the most effective 
measure at detecting AD when compared to healthy controls. Although the abnormality 
cut-off of 88 of the ACE-III had a slightly higher sensitivity (96%) than the ECAS Total 
Score (sensitivity 94% and specificity 96%), it had a much lower specificity (86%) at 
detecting AD. In contrast the abnormality cut-off of 82 of the ACE-III had a lower 


















AD (85%, 98%).  
 
The trade-off between sensitivity and specificity is important, particularly when deciding 
which cut-offs may be best suited for detecting a diagnosis or establishing cognitive 
impairments. Although both are multi-domain assessments, the ECAS and ACE-III are 
screening tests which should be used to indicate whether further neuropsychological 
investigation is warranted. In this situation, sensitivity is usually of more importance than 
specificity, as the screening test should capture all those cases who may have the 
disease/cognitive impairment. Nevertheless, it is important to balance between a small 
increase of sensitivity at the expense of a larger decrease in percentage of specificity (26). 
The higher cut-offs of both tests (110 for the ECAS and 88 for the ACE-III) were more 
sensitive to both diagnoses but with much lower specificity. Therefore, the ECAS Total 
Score with an abnormality cut-off of 105, showed high sensitivity without a large cost of 
specificity. 
 
The ECAS also showed strong validity at detecting cognitive impairments as compared 
with the gold standard of neuropsychological assessment. There was a perfect concordance 
of the ECAS scores and impairment on the anterior functions tests of the 
neuropsychological battery for the bvFTD group with 100% sensitivity, and 100% 
specificity. The only bvFTD patient that was unimpaired on the ECAS was also not 
impaired in the anterior functions’ tests of the neuropsychological battery but showed 
changes in the five behavioural domains of the ECAS. The presentation of behaviour 
change without cognitive impairment in FTD has been previously demonstrated (27). There 
was also good concordance between the deficits detected on the ECAS Total and posterior 


















comprehensive neuropsychological assessment for the AD group. The ECAS Total score 
failed to detect two AD patients, while the ECAS posterior functions composite score failed 
to detect one patient only and the ACE-III failed to detect five patients with cognitive 
impairments as determined by the neuropsychological assessment. The original ECAS 
validation study in people with ALS also involved a comparison against extensive 
neuropsychological assessment, but it was a prospective study where each cognitive domain 
was assessed by three standardised tests (8). Impairment in a domain of the neuropsychological 
assessment was defined when 2 out of 3 tests were impaired. The current study was 
retrospective and included data from routine clinical neuropsychological assessment, in which 
for some domains only two standardised tests were used. So as not to dismiss evidence of 
impairment and to be consistent across all our cognitive domains we defined impairment on a 
domain if one test was impaired only. 
 
These findings indicate the possible utility of the ECAS in a broader clinical setting for the 
screening of the dementias. The ECAS has already been shown to be an effective cognitive 
screen for movement disorders of ALS (4), Parkinson’s Disease, and Progressive 
Supranuclear Palsy (5). Since the total score of the ECAS was more sensitive to bvFTD 
and AD than the ACE-III; and it includes a behavioural interview, the ECAS could be used 
as an alternative for the ACE-III for a cognitive screen in the clinical setting. The ECAS 
also has the additional advantage of being less prone to ceiling effects and is less influenced 
by IQ than the ACE-III (12); and therefore, very useful for a young onset population in a 
dementia clinic.  
 
In the quantitative analysis of the behavioural data, most bvFTD patients tended to have 


















two domains. Although only three behavioural symptoms must be present to meet current 
diagnostic criteria for bvFTD (7), the cut-off of 4 or more behavioural domains affected had a 
higher sensitivity (79% sensitivity and 87% specificity) to differentiate between the diagnoses 
of bvFTD and AD in this study. The current diagnostic criteria may therefore not be as effective 
at differential diagnosis, particularly as some people with AD show behavioural changes as 
revealed here. 
 
Apathy was one of the most prevalent behaviours in both patient groups (bvFTD 100%, AD 
58%), which is consistent with the literature (28-30). Disinhibition was very prevalent in the 
bvFTD group (100%), and perseverative behaviour was the second most common behaviour 
in the AD group (45%, although it was also reported in 80% of bvFTD patients), which is 
congruent with the literature (31,32). Identifying apathy as a behavioural change in the 
screening process could help orientate the carers and clinicians to manage this symptom.   
 
The qualitative thematic analysis of the behavioural interview uncovered a number of themes 
which differentiated between the two patient groups. Themes present in people with bvFTD 
only were centred around loss of control (immediacy, loss of manners, binge eating), changes 
in personality (egocentrism and not being the same person), loss of initiation actions, strange 
beliefs, anosognosia, and accidental oversights/mistakes. The most common theme in bvFTD 
patients was loss of sympathy/empathy, followed by compulsions; both of which have been 
reported previously (33-36). Of note both of these behaviours were also reported in ~a third of 
people with AD. Although changes in sympathy/empathy and compulsions may not help with 
differential diagnosis, they are still important for clinical management. The most common 
themes found in AD only were reduced eating and/or lost weight, avoids cooking, loss 


















(37,38). Avoidance of cooking observed in the AD group seem to emerge from fear of having 
an accident. Awareness of diagnosis in AD unlike the lack of awareness in people with bvFTD 
could play a role in whether people avoid certain activities and the loss in self-confidence. The 
types of behaviour change found in our study was in accord with the results of some previous 
studies; where bvFTD patients have been shown to have more compulsive behaviours, 
increased eating (specifically carbohydrates and binge eating), more selfishness with less social 
awareness, and a lack of insight regarding their own functional impairment when compared to 
AD patients (39-42). However, previous studies have used more quantitative questionnaires, 
where a behaviour is present or not; while in the current study, although this is used for the 
number of domains affected, the descriptions of behaviour change were further defined by 
exploring the interviews qualitatively through thematic analysis. The findings demonstrate that 
certain behaviours may help in differential diagnosis.  
 
The overlap in cognitive presentations with memory and executive dysfunction between these 
two types of dementia can make differential diagnosis very difficult. The cognitive section of 
the ECAS has corresponding limitations and therefore although able to detect each diagnosis, 
cannot reliably differentiate between the two. However, the results of the ECAS behavioural 
screen proved effective in differentiating bvFTD from AD. It is noteworthy that the ECAS 
posterior composite score was sensitive to the bvFTD group, although less than the AD 
group, and 75% of the bvFTD group were impaired on this score. People with bvFTD can 
experience memory impairments, as the processes of encoding and retrieving often require 
executive functions for organizing the information (43). In parallel, the ECAS anterior 
composite score was also sensitive to AD, but less than the bvFTD group, and 84% were 
impaired on this measure. It is well recognized that people with AD may also experience 


















of divided attention (44). In addition, we have demonstrated that the between group 
comparison of the ECAS composite scores may  have been under powered, particularly 
given the relatively small sample size of the bvFTD group. Nevertheless, despite this overlap 
in presentation, distinctive behavioural features were present which distinguished between the 
two groups. Of note, the ECAS behavioural screen was designed to detect behaviour 
changes which are typical of bvFTD, and was therefore closely based on the diagnostic 
criteria (7). It was also developed to provide a standardised method for measuring and 
assessing these changes. Given that the bvFTD group were diagnosed on the basis of this 
same criteria, it is inevitable that the screen would be sensitive to the types of behaviour 
change in this group.” 
 
We had expected to find a difference between the bvFTD and AD samples with the composite 
scores, as one study previously found the ECAS posterior score to be sensitive at differentiating 
between AD and ALS patients (6). However, ALS presents with a heterogenous spectrum of 
cognitive change, with at least 50% of patients typically cognitively intact. In line with this 
only 50% of their ALS patients were impaired on the ECAS Total score, whereas 94% of our 
bvFTD sample was impaired, indicating more severe and extensive impairment in the current 
patient group. Furthermore, the AD group from this previous study (6) were older than the 
current study (mean age of 67.19 vs 61.18 years old respectively), and it is possible that early 
onset AD (< 65 years of age) may have a slightly different cognitive profile from late onset 
(45,46). Nevertheless, a further study which compared the Greek version of the ECAS with the 
ACE-III (22) found similar results to those reported here; in which both composite scores were 
sensitive to AD, with the posterior composite score being the most sensitive measure. Strengths 
of this study were its thorough investigation of the clinical validity of the ECAS with these 


















imaging, CSF, and/or genetic analysis). The validation against comprehensive 
neuropsychology reinforces the use of the ECAS as a useful screening tool for the cognitive 
assessment of patients with and without a motor disorder. Although some of the behavioural 
differences between bvFTD and AD have been investigated previously in other studies with 
quantitative questionnaires and semi structured interviews, this is the first study that analyses 
and compares the different themes reported on the ECAS behavioural screen in people with 
bvFTD and AD. The limitations of this study include the sample size, particularly for the 
bvFTD group, which resulted in a lack of power for the comparison between patient groups. 
Furthermore, the retrospective study design limited the analysis of the available 
neuropsychological test data. 
 
The findings demonstrate that the ECAS could be used by clinicians to evaluate suspected 
frontal lobe disorders and AD. Using the ECAS as a first line screen for cognitive 
impairment where there is a suspicion of bvFTD could speed up the process of assessment, 
diagnosis and treatment for this disease. Behavioural interviews with the carers add to the 
utility of the cognitive screens and may bring to light possible changes which may be 
important for clinical management. The ECAS could also heighten awareness in carers of 
the possible behavioural changes the patients could experience, which may facilitate 




The ECAS was successful in assessing the profile of cognitive and behavioural impairment 
in both bvFTD and AD. The combined score for memory and visuospatial assessment was 


















functions was sensitive to bvFTD. The ECAS also shows strong validity against full 
neuropsychological assessment and was more successful than the ACE-III at detecting 
impairment in both bvFTD and AD. The inclusion of a behavioural interview in the ECAS 
makes it particularly suitable to aid in the diagnosis of behavioural abnormalities related to 
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ACE-III Total 
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69.92  (±15.24) 32-98 




behavioural variant Frontotemporal Dementia (bvFTD), Alzheimer’s Disease (AD), Edinburgh 
Cognitive and Behavioural ALS Screen (ECAS), Addenbrooke’s Cognitive Examination 























Table 2: Sensitivity and specificity of the ACE-III and ECAS tests scores in detecting bvFTD 
and AD vs controls 
 bvFTD  AD 
 Abnormality 
Cut-off 
Sensitivity Specificity Sensitivity Specificity 
ACE-III Total 82 .786 .977 .833 .977 
ACE-III Total 88 .857 .864 .958 .864 
ECAS Total 105 .938 .958 .938 .958 
ECAS Total 110 1.000 .812 .969 .812 
Language 26 .750 .750 .656 .750 
Fluency 14 .875 .937 .594 .937 
Executive 33 .813 .958 .844 .958 
Anterior 
Composite 
77 .938 .917 .844 .917 
Memory 13 .750 .958 .906 .958 
Visuospatial 10 .438 .917 .531 .917 
Posterior 
Composite 
24 .750 .958 .969 .958 
ECAS anterior composite (language, fluency, and executive) and ECAS posterior composite 
(memory and visuospatial), Abnormality cut-offs are both standard and borderline for both 



































Table 3: Themes from the analysis of the behavioural interview 
bvFTD (n=15) AD (n=25) 
bvFTD % Themes AD % 
 Impulsivity and Disinhibition  
73 Buying Impulsively 12 
66 Immediacy/Impatience  
66 Loss of manners or decorum  
60 Impulsive Decisions 33 
60 Offensive/Inappropriate jokes or comments 33 
46 Aggression 8 
33 Hypersexual behaviour 8 
 Apathy  
80 Loss of interest in normal activities/hobbies 56 
33 Emotional flatness 24 
33 Loss of initiation actions  
20 Neglect of self-care 12 
 Social interactions  
100 Loss of sympathy/Empathy 32 
80 Reduced social interest 32 
33 Egocentrism  
 Perseverative Behaviour  
80 Simple repetitive movements 24 
73 Compulsive behaviour 32 
40 Hoarding 20 
26 Fixed Routine 12 
 Eating and preparing food  
80 Eats more carbs 24 
46 Binge eating  
 Eats less/lost weight 32 
 Avoids cooking 24 
 Psychosis  
46 Paranoia 24 
20 hallucinations 12 
20 Strange beliefs  
 Other  
60 Accidental oversights/Mistakes  
46 Disorientated 20 
46 Not the same person/Change personality  
26 Lack of awareness/Anosognosia  
 Lost confidence 33 
 Stopped reading 24 
 Solving problems 20 
 Misplace items 8 





























ECAS Anterior composite (language, fluency, and executive), ECAS Posterior composite 






















Figure 2: Percentage of the number of behavioural domains affected  
 
 










































Supplementary information for the article 
 
Supplementary Table 1: Neuropsychological Tests  
Cognitive 
Domain 
Name of test Reference 
Cognitive 
Screen 
Addenbrooke’s Cognitive Examination 
(ACE-III) 
Noone, 2015 
Fluency Controlled Oral Word Association 
(FAS) 
Benton and Hamsher, 1983 
Category (Animal) Naming Isaacs and Kennie, 1973 
Language The Graded Naming Test Warrington, 1997 
Test of Reception of Grammar (TROG) Bishop, 1989 
Executive Trail Making Test Reitan and Wolfson, 1985 
The Sorting Test (The Delis-Kaplan 
Executive Function System)  
Delis, Kaplan and Kramer, 
2001 
Memory Free and Cued Selective Reminding Test 
(FSCRT) 
Sarazin, et al., 2007 
BIRT Memory and Information 
Processing Battery Story and Figure 
Recall 
Coughlan, Oddy and 
Crawford, 2007 
Visuospatial  The Visual Object and Space Perception 
Battery  
Warrington and James, 1991 
BIRT Memory and Information 
Processing Battery Figure copy 
Coughlan, Oddy and 
Crawford, 2007 









































Supplementary Table 2: bvFTD and AD patients impairment on the ECAS, ACE-III and 























6 X X X X X X 
2 X X X ✓ X X 
1 X X X X X ✓ 
2 ✓ X X X X X 
1 ✓ ✓ ✓ ✓ ✓ X 
1  X X X X X 
1 X X X X   
1 X X X ✓   
1  X X X   
AD 
15 X X X X X X 
3 ✓ X X X X X 
2 X X ✓ X X X 
1 X ✓ ✓ ✓ X X 
1 ✓ X ✓ X X X 
1 ✓ ✓ ✓ X X X 
1 X X X X  X 
5  X X X X X 
1  X X X  X 
1 X X X X   
1  X X X   
Normal Range (✓), Impaired Range (X), Neuropsychology Anterior Domains: X is marked 
for impairment on language and/or fluency and/or executive functions in the comprehensive 
neuropsychological assessment. Neuropsychology Posterior Domains: X is marked for 










































Alzheimer’s Disease (AD), behavioural variant Frontotemporal Dementia (bvFTD), Number 






AD (N=24) bvFTD (N=15)   AD bvFTD 
Disinhibition 33% 100% 
Apathy and Inertia 58% 100% 
Loss of Sympathy or Empathy 29% 87% 
Perseverative 45% 80% 
Hyperorality and Altered Food Preferences 25% 80% 
